Drugs / AR882
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT04646889 | Jan 2021 → Jun 2022 | impaired renal function disease | Arthrosi Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04508426 | Jul → Aug 2020 | — | Arthrosi Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04314986 | Jun → Sep 2019 | — | Arthrosi Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04347005 | Jan → Jul 2019 | — | Arthrosi Therapeutics | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07116746 | Dec 2025 → Nov 2026 expected | gout | Arthrosi Therapeutics | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05253833 | Aug 2022 → Aug 2024 | gout | Arthrosi Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT05119686 | Nov 2021 → Nov 2022 | gout | Arthrosi Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT04155918 | Feb → Sep 2020 | gout | Arthrosi Therapeutics | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06603142 | Apr 2024 → Apr 2026 overdue | gout | Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd | Active not recruiting | No outcome recorded |
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT06846515 | Mar 2025 → Aug 2026 | gout | Arthrosi Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT06439602 | Jun 2024 → Mar 2026 | gout | Arthrosi Therapeutics | Completed | Met primary |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2026-05-21 | Sobi, Inc. | Results Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout sobi.com ↗
Both doses of pozdeutinurad met the primary efficacy endpoint, defined as the proportion of patients achieving a serum uric acid (sUA) level < 6 mg/dL at month 6 ( 75 mg: 69.2% vs 8.1%; p < 0.0001; 50 mg: 56.6% vs 8.1%; p < 0.0001 ). |
| 2024-09-03 | Arthrosi Therapeutics | Regulatory Arthrosi Therapeutics Receives FDA Fast Track Designation for AR882 in Tophaceous Gout arthrosi.com ↗
the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to AR882 for the potential treatment of clinically visible tophi in patients with gout. |
| 2024-05-31 | Arthrosi Therapeutics | Results Arthrosi Announces Multiple Presentations at the European League Against Rheumatism (EULAR) Congress 2024 arthrosi.com ↗
AR882, a Novel and Selective URAT1 Inhibitor, Significantly Reduced Tophi in Patients with Chronic Gouty Arthritis: Results of 12-month Outcome from a Global Trial using Digital Caliper Measurements and Dual Energy Computed Tomography |
| 2023-11-07 | Arthrosi Therapeutics | Results Arthrosi to Present Positive Phase 2 Data for its Novel Selective URAT1 Inhibitor AR882 in Patients with Tophaceous Gout at ACR Convergence 2023 arthrosi.com ↗
Arthrosi Therapeutics, Inc., a clinical-stage biotechnology company developing treatments for gout that dissolve uric acid crystals and prevent joint damage, today announced new clinical data from its phase 2 AR882-203 study in patients with tophaceous gout. |
| 2023-01-05 | Arthrosi Therapeutics | Results Arthrosi Announces Positive Topline Results For AR882 Phase 2B Study arthrosi.com ↗
Arthrosi Therapeutics, Inc., a clinical-stage biotechnology company, today announced positive topline results from its Phase 2b clinical study of AR882 for the treatment of chronic gout, providing a strong foundation to advance into Phase 3 clinical development. |
| 2022-08-09 | Arthrosi Therapeutics | Results Arthrosi Completes AR882 Renal Impairment Study arthrosi.com ↗
Mean serum urate levels (sUA) were reduced between 50 to 60 percent, regardless of mild or moderate impairment, or normal renal function. |
| 2021-11-02 | Arthrosi Therapeutics | Results Arthrosi Presents AR882 Posters at ACR 2021 arthrosi.com ↗
In subjects with various renal functions, a single dose of AR882 was found to produce mean serum urate levels (sUA) between 50 to 60 percent, regardless of mild, moderate impairment, or normal renal function. |
| 2021-06-01 | Arthrosi Therapeutics | Results Arthrosi Therapeutics, Inc. Announces Impressive Phase 2a Study Results arthrosi.com ↗
Arthrosi Therapeutics, Inc. announced results from its Phase 2a study investigating the efficacy and safety of its potent urate lowering agent AR882. |
All press releases naming this drug 18 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AR882 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06846515 ↗ |
| Route | Oral | “Orally Administered” NCT04508426 ↗ |